Vinblastine (NSC-49842) sulfate

Catalog No.S4505 Synonyms: Vincaleukoblastine sulfate salt, 29060-LE, Exal, Velban, Velbe

For research use only.

Vinblastine sulfate (NSC49842, Vincaleukoblastine sulfate salt, 29060-LE, Exal, Velban, Velbe) inhibits microtubule formation and suppresses nAChR activity with IC50 of 8.9 μM in a cell-free assay, used to treat certain kinds of cancer. Vinblastine sulfate induces autophagy and apoptosis.

Vinblastine (NSC-49842) sulfate Chemical Structure

CAS No. 143-67-9

Selleck's Vinblastine (NSC-49842) sulfate has been cited by 28 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Vinblastine sulfate (NSC49842, Vincaleukoblastine sulfate salt, 29060-LE, Exal, Velban, Velbe) inhibits microtubule formation and suppresses nAChR activity with IC50 of 8.9 μM in a cell-free assay, used to treat certain kinds of cancer. Vinblastine sulfate induces autophagy and apoptosis.
Targets
nAChR [1]
(Adrenal Chromaffin Cells)
8.9 μM
In vitro

The average terminal half-lives of Vinblastine is 14.3 h. When incubated in freshly isolated rat hepatocytes, VLB penetrates rapidly and intensely into the cells, probably through a passive diffusion mechanism followed by tight cellular binding[3]. Vinblastine inhibits the angiogenic response induced by adrenomedullin and is also positive for mitotic slippage, causing micronuclei in mononucleate cells with cytokinesis block[4]. vinblastine gives significant increase in micronucleated mononucleated cells at concentrations that produced approximately 50% cell death and cytostasis or less as calculated using RPD, RICC and RCC[2].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
COLO 320 human colorectal carcinoma cell line NIXFVFVHfW6ldHnvckBie3OjeR?= M4\4TWlvKH[rdILvJINwdmOnboTyZZRqd25icnXxeYlz\WRidH:gb4ltdCB3MDWgc4YhS0:OTzCzNlAhcHWvYX6gZ49td3KnY4ThcEBk[XKlaX7vcYEh[2WubDDsbY5mNCCHQ{WwQVAvODhizszN MnfINVI{PjF|OUe=
LNCaP human prostate cancer cell line MnKwSpVv[3Srb36gZZN{[Xl? NH\WWYtKdiC4aYTyc{Bkd26lZX70doF1cW:wIILldZVqemWmIITvJItqdGxiNUClJI9nKEyQQ3HQJIh2dWGwIIDyc5N1[XSnIHPhcoNmeiClZXzsJIxqdmVuIFXDOVA:OC53IN88US=> MUOxNlM3OTN7Nx?=
K562 cell NGjPe3pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnjiTY4hfmm2cn:gbY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3RiaIXtZY4h[2i{b37pZ{BugWWub3flco92eyCuZYXr[Y1q[SCNNU[yJINmdGxiZ4Lve5RpNCCLQ{WwQVAvODBzIN88US=> MUKxNlg2Ojd4OB?=
T47D cells NF:3c|VHfW6ldHnvckBie3OjeR?= NHfURopKdiC4aYTyc{Bkd26lZX70doF1cW:wIILldZVqemWmIITvJItqdGxiNUClJI9nKFR2N1SgbJVu[W5iYoLlZZN1KGS3Y4ThcEBk[XKlaX7vcYEh[2WubDDsbY5mNCCHQ{WwQVAvODhizszN NHz6VVcyOjN4MUO5Oy=>
K562 cell Mk\qVJJwdGmoZYLheIlwdiCjc4PhfS=> MWC0PEBp NYDDVJp1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJIFnfGW{IES4JIhzeyxiSVO1NF0xNjByMTFOwG0> M3jMdFE6OjJyMEG4
ACHN cells NYDFWVNHS3m2b4TvfIlkcXS7IHHzd4F6 NETkflM1QCCq NFTo[mpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCS0iQIHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEmFNUC9NlIvPyEQvF2= MV:xPVQ3Pzh5Nx?=
A375 cells M4XuR2N6fG:2b4jpZ4l1gSCjc4PhfS=> MWO0PEBp NGm3dFVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOzd3IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEmFNUC9O{4zKM7:TR?= NVLP[4pHOTl2Nke4O|c>
C32 cells MoGwR5l1d3SxeHnjbZR6KGG|c3H5 MV[0PEBp MUHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDN|Ih[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygTWM2OD1|IN88US=> NHKxVnQyQTR4N{i3Oy=>
LNCAP cells MVfDfZRwfG:6aXPpeJkh[XO|YYm= M3vGeFQ5KGh? MkTIR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUG5ESVBiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2yPU4{KM7:TR?= MmGyNVk1Pjd6N{e=
Huh-7D12 cells NEHYc2JEgXSxdH;4bYNqfHliYYPzZZk> NFeycmc1QCCq MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIeYguP0RzMjDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVQ2NjZizszN NICzVW8yQTR4N{i3Oy=>
COR-L23 cells MWHDfZRwfG:6aXPpeJkh[XO|YYm= NE\xZpQ1QCCq MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDU3IuVDJ|IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEmFNUC9OFUvPSEQvF2= MUCxPVQ3Pzh5Nx?=
142BR cells M2LUVWN6fG:2b4jpZ4l1gSCjc4PhfS=> NH3VbFA1QCCq MXXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjCxOFJDWiClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUO3MlYh|ryP M2PYXFE6PDZ5OEe3
HT-29 cells M{TDWGN6fG:2b4jpZ4l1gSCjc4PhfS=> MlvJOFghcA>? MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRUKGG|c3H5MEBKSzVyPUCuOVUh|ryP MYCyNVkzODd4Mh?=
A549 cells MX3Qdo9tcW[ncnH0bY9vKGG|c3H5 MUe0PEBp NIK3bJhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UV{Bie3OjeTygTWM2OD1{LkO2JO69VQ>? MYKyNlU1PjZ5NB?=
DU145 cells NIXpXnhRem:uaX\ldoF1cW:wIHHzd4F6 NVTuOlFLPDhiaB?= MUPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESXMUS1JINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGOgZZN{[XluIFnDOVA:PC5{NTFOwG0> NVXaWmpCOjJ3NE[2O|Q>
SK-MEL-5 cells MkXjVJJwdGmoZYLheIlwdiCjc4PhfS=> NYTDVHhoPDhiaB?= Ml7qRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVSz3NSWwuPSClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRUKGG|c3H5MEBKSzVyPUGuO|Qh|ryP NGfMbIwzOjV2Nk[3OC=>
HepG2 cells NF:y[WNRem:uaX\ldoF1cW:wIHHzd4F6 NHjtbHA1QCCq MWnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGOgZZN{[XluIFnDOVA:OC5zNjFOwG0> NYnINY12OjJ3NE[2O|Q>
HT-29 cells M3O1NXBzd2yrZnXyZZRqd25iYYPzZZk> MWW0PEBp MoDmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVD2yPUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTTJIF{e2G7LDDJR|UxRTFzLkG4JO69VQ>? MXKyNlU1PjZ5NB?=
MCF7 cells MWfQdo9tcW[ncnH0bY9vKGG|c3H5 NYXDeVR2PDhiaB?= NW\FeGMxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHMh[XO|YYmsJGlEPTB;MkSuNFgh|ryP MmfmNlI2PDZ4N{S=
MDA-MB-231 cells MYDQdo9tcW[ncnH0bY9vKGG|c3H5 M2LkWFQ5KGh? MoPVRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFNiYYPzZZktKEmFNUC9N|EvPTJizszN M3foUVIzPTR4Nke0
rat REF52 cells MXPGeY5kfGmxbjDhd5NigQ>? MUmwMlEh|ryP M{jKRVMxKG2rboO= Mm\OTY5lfWO2aX;uJI9nKG2rY4LveJVjfWynIHTldI9tgW2ncnn6ZZRqd25iaX6gdoF1KFKHRkWyJINmdGy|IHH0JFAvOSC3TTDh[pRmeiB|MDDtbY5{KGK7IH\seY9z\XOlZX7j[UBie3OjeR?= NYn0N3hlOjN7NEe4NlY>
HepG2 cells M3v4eGN6fG:2b4jpZ4l1gSCjc4PhfS=> MYq3NkBp NIX2R3pEgXSxdH;4bYNqfHliYXfhbY5{fCCjZILpZY16[2mwLYLld4l{fGGwdDDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFU3KM7:TR?= MojENlM4ODhyMUC=
HepG2 cells M{nve2N6fG:2b4jpZ4l1gSCjc4PhfS=> M2PoVFczKGh? MkDBR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjBzOTFOwG0> NXnOTmF6OjN5MEiwNVA>
K562 cells NUHkeoxKS3m2b4TvfIlkcXS7IHHzd4F6 MUW3NkBp MV3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xOTZizszN NGH1UWIzOzdyOECxNC=>
MDA-MB-231 cells NHXWOoJEgXSxdH;4bYNqfHliYYPzZZk> M4TZXlczKGh? MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFg{KM7:TR?= NIDHNVAzOzdyOECxNC=>
MCF7 cells M3fvPWN6fG:2b4jpZ4l1gSCjc4PhfS=> MVG3NkBp MnLmR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODB5IN88US=> M3PiUlI{PzB6MEGw
SCL6 cells M{T2dmN6fG:2b4jpZ4l1gSCjc4PhfS=> MVvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTR2w3KGOnbHzzJIJ6KE2WVDDhd5NigSxiRVS1NF03NjFizqzt Ml3iNVI5QDB|MUS=
SCL9 M3PwRmN6fG:2b4jpZ4l1gSCjc4PhfS=> M{\GZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNEVDliY3XscJMh[nliTWTUJIF{e2G7LDDFSF02NjNizszN NXXXfoJDOTJ6OECzNVQ>
KATO III cells Ml2zR5l1d3SxeHnjbZR6KGG|c3H5 M{DlZWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtCXE9iSVnJJINmdGy|IHL5JG1VXCCjc4PhfUwhTUR3ME22MlEh|ryP NXzPXJJNOTJ6OECzNVQ>
NUGC4 cells MmTCR5l1d3SxeHnjbZR6KGG|c3H5 NHnGXFhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPXUeFNDDj[YxteyCkeTDNWHQh[XO|YYmsJGVFPTB;NT6zJO69VQ>? NX;oRldSOTJ6OECzNVQ>
UACC903 cells Mn;3R5l1d3SxeHnjbZR6KGG|c3H5 M1zhWVQ5KGh? NHXCfZREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWSUOFOUCzJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGOgZZN{[XluIFnDOVA:OS54NTFOwG0> NHjPU2szOTl{MEe2Ni=>
K562 cells MlvtSpVv[3Srb36gZZN{[Xl? NEPpPZpKdmirYnn0bY9vKG:oIIT1ZpVtcW5icH;sfY1memm8YYTpc44hcW5iaIXtZY4hUzV4MjDj[YxteyxiSVO1NF0xNjF|IN88US=> M3PhflIxPTR4OUiw
BxPC3 cells NH;4Z|JRem:uaX\ldoF1cW:wIHHzd4F6 M4\JNFQ5KGh? NUPrZYxuSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDCfHBEOyClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRUKGG|c3H5MEBKSzVyPUGuNVMh|ryP NEfGPFkzOjV2Nk[3OC=>
Assay
Methods Test Index PMID
Western blot GRP78 ; p-eIF2 ; p-JNK / c-Caspase-7 / c-PARP ; ERK / p-ERK / Mcl-1 / Bad / Bid / Noxa 19674193 20371726
Immunofluorescence α-tubulin / Acetyl tubulin 30120268
Growth inhibition assay Cell viability 27114800
In vivo Vinblastine is a widely used anticancer drug with undesired side effects [6]. A combination of VBL and RAP at very low doses against human HCC gets a satisfactory antiangiogenic effect in vivo[4]. The clinically relevant dose of vinblastine inhibits palmitoylation of tubulin in vivo in CEM cells (effect on depalmitoylation of tubulin)[5].

Protocol (from reference)

Cell Research:

[2]

  • Cell lines: Chinese hamster ovary (CHO) cells
  • Concentrations: 1% (v/v) (dissolved in DMSO)
  • Incubation Time: 3h
  • Method:

    Six-well treatment plates are set up that contained 5 × 104 cells/mL in each well, suspended in 3 mL culture medium, and these are treated with vinblastine for 3 h followed by 21 h growth.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 909.05
Formula

C46H58N4O9.H2SO4

CAS No. 143-67-9
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02840409 Recruiting Drug: Vinblastine|Drug: Bevacizumab Low Grade Glioma The Hospital for Sick Children|Hoffmann-La Roche August 2016 Phase 2
NCT02670707 Recruiting Drug: Cytarabine|Drug: Vinblastine/prednisone Langerhans Cell Histiocytosis Baylor College of Medicine March 7 2016 Phase 3

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Vinblastine (NSC-49842) sulfate | Vinblastine (NSC-49842) sulfate supplier | purchase Vinblastine (NSC-49842) sulfate | Vinblastine (NSC-49842) sulfate cost | Vinblastine (NSC-49842) sulfate manufacturer | order Vinblastine (NSC-49842) sulfate | Vinblastine (NSC-49842) sulfate distributor